Soranni (Sorafenib)

Indications

Including: unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and local recovery that is refractory to radioactive iodine therapy

Hair or metastasis, and advanced differentiated thyroid cancer.

Dose and administration method

1. Method of administration

• 400mg (2 tablets) orally, twice a day, on an empty stomach.
• To deal with suspected adverse drug reactions, treatment may need to be interrupted and/or dose reduced. The dose can be reduced To 400mg once a day or to 400mg, once every other day.

2. Dosage specifications

• Tablets, 200mg.

3. Contraindications

• People who are known to be allergic to sorafenib or any other components of the drug should not use sorafenib.
• In patients with squamous cell lung cancer, sorafenib is contraindicated in combination with carboplatin and paclitaxel.

Warnings and Precautions

• Myocardial ischemia and/or infarction: consider temporarily or permanently discontinuing sorafenib.
• Bleeding: If bleeding requires medical intervention, consider discontinuing sorafenib.
• Hypertension: 6 weeks before treatment, regularly monitor blood pressure every week. Follow-up treatment should also be monitored regularly.
• Skin toxicity: Interrupt and/or reduce the dose. Severe or persistent skin toxicity, or pregnant Stop taking the medication when you suspect Stevens-John syndrome and toxic epidermal necrolysis.
• Gastrointestinal perforation: stop taking sorafenib.
• Prolonged QT interval: Patients with high risk of ventricular arrhythmia regularly monitor ECG and electrolyte levels.
• Drug-induced hepatotoxicity: monitor liver function regularly; stop if there is an unexplained rise in transaminase Stop taking medicine.
• Embryo toxicity: It is recommended that women of childbearing age avoid pregnancy when taking the drug.
• Thyroid-stimulating hormone (TSH) damage in differentiated thyroid cancer (DTC): monitor TSH once a month,

(Please read this notice carefully and take the medicine according to this notice or under the guidance of a doctor)

• Thyroid replacement therapy is suitable for patients with thyroid cancer.

Adverse reactions

The most common adverse reactions related to sorafenib (≥20%): diarrhea, fatigue, infection, baldness, Hand and foot skin reactions, rash, weight loss, anorexia, nausea, gastrointestinal pain and abdominal pain, high blood pressure and blood.

storage method

Shading, cool and dry place